Session IV The application of new vaccine technologies to control high consequence animal diseases

1. The application of new vaccine
technologies to control high
consequence animal diseases
Bryan Charleston

2. • Inactivated
• Live attenuated
• Recombinant sub-unit
• Rationally attenuated
• RNA/ DNA vaccines
Veterinary Vaccines
Development
cost

3. BVDV
(Npro deletion + Rnase inactivation)
C Erns
Npro
Wild type
RNase neg.
+ Npro deletion
H349D
5 codons
C Erns

4. • Baculovirus expression VLP platform technology
• Builds on existing collaboration and substantial investment from Defra,
Wellcome, BMGF and MAH, to develop stabilised FMD VLPs for vaccination.
• Quadrivalent vaccine (O, A, SAT-1 and SAT-2 serotypes).
FMD VLP Vaccine

5. Respiratory Syncytial Virus Antigenic Site is Not Present in Post-fusion F
Pre-fusion Post-fusion
N
N
C
C
N
C
C
N
α4
α5post
Structural Vaccinology

6. ChAdOx1 for Rift Valley Fever
In use for other HUMAN vaccines
including COVID-19
Gn/Gc Genes
responsible for
immunity
RVF
Vir us
ChAdOx1
technology
+
Rift Valley Fever Non-
Replication Viral Vector
Vaccine (Zoonotic
Disease)

7. Modification of viral vector insert can significantly
improve immune responses
Mercado, N.B., Zahn, R.,
Wegmann, F. et al. Single-
shot Ad26 vaccine protects
against SARS-CoV-2 in
rhesus
macaques. Nature 586, 583
–588 (2020).
https://doi.org/10.1038/s415
86-020-2607-z

8. 0 7 14 21 28 35 42 49 56
101
102
103
104
105
EPT
Boost
0 14 28 42 56
102
103
104
ND
50
Boost
0 7 14 21 28 35 42 49 56
101
102
103
104
105
Days post-immunisation
EPT
Boost
0 14 28 42 56
101
102
103
104
105
Days post-immunisation
ND
50
Boost
Prime-boost
Prime-only
ChAdOx1 nCoV-19 – antibody responses
RBD ELISA
pVNT
VNT
Graham et al., 2020
FL-S ELISA

9. RBD ELISA pVNT
RBD-SpyVLP - antibody responses
0 7 14 21 28 35 42 49 56
101
102
103
104
105
Days post-immunisation
RBD
EPT
Boost
0 7 14 21 28 35 42 49 56
102
103
104
Days post-immunisation
ND
50
Boost
21 35 56
101
102
103
104
105
Days post-immunisation
Boost
100g FL-S 5g RBD-VLP 50g RBD-VLP
VNT
Tan et al., 2020

10. Self amplifying SARS-CoV-2 vaccine
0 7 14 21 28 35 42 49 56
0
500
1000
1500
2000
2500
Days post-immunisation
IFN-
S-C/10
6
cells
Boost
0 7 14 21 28 35 42 49 56
101
102
103
104
Days post-immunisation
RBD
EPT
<
Boost
PC 0 7 14 21 28 35 42 49 56 PC
102
103
104
Days post-immunisation
ND
50
Boost
<101
35 56 35 56 35 56 35 56 35 56
101
102
103
Days post-immunisation
<
PC
0 7 21 35 49 56
0.0
0.5
1.0
1.5
2.0
Days post-immunisation
IFN-+TNF-+
cells
(%)
Boost
0 7 21 35 49 56
Days post-immunisation
Boost
10 g LNP-nCoVsaRNA
10 g LNP-nCoVsaRNA-02
1 g LNP-nCoVsaRNA-02
0.1 g LNP-nCoVsaRNA-02
ICS - CD4 T cells ICS - CD8 T cells
RBD ELISA pVNT VNT
IFN-γ ELISpot
Unpublished data

11. Pirbright Institute